VC  Third Rock Ventures

http://www.thirdrockventures.com





     Office Locations:

29 Newbury Street, 301
Boston, MA 02116
Phone: 617-585-2000
Fax: 617-859-2891

Get all office locations for this firm with a National Database subscription or Silicon Valley Database subscription.
 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Founded in 2007, Third Rock Ventures has over $1.3 billion under management for exclusive investment in life-sciences, primarily in biotechnology, biopharmaceutical, and medical device companies. The firm's strategy is to lead investing rounds and continue with a significant stake in uniquely innovative life sciences businesses, making an initial investment of up to $35 million. Third Rock was founded by four ex-Millennium Pharma executives, including former Millennium CEO, Mark Levin. The firm announced the final closing of Fund III (March 2013), raising $516 million in an oversubscribed fund. Third Rock announced the closing of Third Rock Ventures IV, LP October of 2016, raising $616 million in an oversubscribed fund.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or Silicon Valley Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Abbie Celniker Ph D Partner
    Alexis Borisy Partner
    Cary Pfeffer MD Partner
    Charles Homcy MD Partner
    Frank T. Gentile Ph D Venture Partner

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      04/09/2018


      Constellation Pharmaceuticals


      MA


      $100,000,000


      


      03/22/2018


      Rheos Medicines


      MA


      $60,000,000


      Series A


      12/14/2017


      Relay Therapeutics


      MA


      $63,000,000


      Series B


      10/09/2017


      PanOptica


      NJ


      $11,000,000


      Series B


      05/02/2017


      Magenta Therapeutics


      MA


      $50,000,000


      Series B


     

    Portfolio companies include:


      Ablexis
        web link


      Afferent Pharmaceuticals
        web link


      Agios Pharmaceuticals
        web link


      Alcresta
        web link


      Allena Pharmaceuticals
        web link


      Alnara Pharmaceuticals
        web link


      bluebird bio
        web link


      Blueprint Medicines
        web link


      Cibiem
        web link


      Constellation Pharmaceuticals
        web link


      CytomX
        web link


      Editas Medicine
        web link


      Eleven Biotherapeutics
        web link


      Ember Therapeutics
        web link


      Foundation Medicine
        web link


      Fulcrum Therapeutics
        web link


      Global Blood Therapeutics
        web link


      Goldfinch Bio
        web link


      Igenica
        web link


      Kala Pharmaceuticals
        web link


      Lotus Tissue Repair
        web link


      Magenta Therapeutics
        web link


      MyoKardia
        web link


      Neon Therapeutics
        web link


      NinePoint Medical
        web link


      Nurix
        web link


      PanOptica
        web link


      Pliant Therapeutics
        web link


      Relay Therapeutics
        web link


      REVOLUTION Medicines
        web link


      Rheos Medicines
        web link


      Rhythm
        web link


      SAGE Therapeutics
        web link


      Seventh Sense Biosystems
        web link


      TARIS Biomedical
        web link


      Topica Pharmaceuticals
        web link


      Voyager Therapeutics
        web link


      Warp Drive Bio
        web link


      Zafgen
        web link


     

    Recent News:


      There is no recent news for Third Rock Ventures.